|
|
||||||||
From the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.
PURPOSE. To determine the effect of systemic anti-CD154 monoclonal antibody on the survival of orthotopic murine corneal transplants.
METHODS. BALB/c mice were used as recipients of syngeneic, multiple minor
histocompatability (H)disparate, or major histocompatibility complex
MHC-mismatched corneal transplants. Recipient beds were either
avascular (normal risk) or neovascularized (high risk). Mice were
randomized to receive either anti-CD154 antibody or control
immunoglobulin by intraperitoneal injection at surgery and once weekly
after surgery. After orthotopic corneal transplantation, all grafts
were evaluated for signs of rejection by slit lamp biomicroscopy over 8
weeks. The high-risk transplants were continuously observed until week
18 after the therapy was discontinued at week 8. Allospecific
delayed-type hypersensitivity (DTH) was evaluated after transplantation
in high-risk graft recipients. Frequency of interferon
(IFN)-
secreting T cells in the hosts was measured by enzyme-linked
immunospot (ELISPOT) assay.
RESULTS. In normal-risk transplantation, the 8-week survival rate improved from
25% in control mice to 88% in anti-CD154treated hosts of minor
Hdisparate grafts (P = 0.0087) and from 78% in
control mice to 100% in anti-CD154treated recipients of
MHC-mismatched transplants (P = 0.177). Of
particular significance, in high-risk transplantation, anti-CD154
therapy dramatically enhanced the survival of both minor H and
MHC-disparate corneal transplants to 100% (P =
0.0001) and 92% (P = 0.0002), respectively. In
addition, the anti-CD154treated mice did not exhibit allospecific
immunity. However, termination of anti-CD154 led to some loss in graft
survival, especially among high-risk minor Hdisparate grafts. The
frequency of IFN-
producing T cells was significantly reduced in
anti-CD154treated hosts.
CONCLUSIONS. Continuous suppression of the CD40-CD154 costimulatory pathway promotes the acceptance of corneal transplants, regardless of the degree of allodisparity or preoperative risk. The beneficial effect of anti-CD154 treatment may be due in part to inhibition of Th1-mediated responses.
This article has been cited by other articles:
![]() |
L. Chen, S. Huq, H. Gardner, A. R. de Fougerolles, S. Barabino, and M. R. Dana Very Late Antigen 1 Blockade Markedly Promotes Survival of Corneal Allografts Arch Ophthalmol, June 1, 2007; 125(6): 783 - 788. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Watson, A. J. T. George, and D. F. P. Larkin Differential effects of costimulatory pathway modulation on corneal allograft survival. Invest. Ophthalmol. Vis. Sci., August 1, 2006; 47(8): 3417 - 3422. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Huq, Y. Liu, G. Benichou, and M. R. Dana Relevance of the Direct Pathway of Sensitization in Corneal Transplantation Is Dictated by the Graft Bed Microenvironment J. Immunol., October 1, 2004; 173(7): 4464 - 4469. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Dana Corneal Antigen-Presenting Cells: Diversity, Plasticity, and Disguise The Cogan Lecture Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 722 - 727. [Full Text] [PDF] |
||||
![]() |
J. Yamada, K. Maruyama, Y. Sano, S. Kinoshita, Y. Murata, and J. Hamuro Promotion of Corneal Allograft Survival by the Induction of Oxidative Macrophages Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 448 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ardjomand, J. C. McAlister, N. J. Rogers, P. H. Tan, A. J. T. George, and D. F. P. Larkin Modulation of Costimulation by CD28 and CD154 Alters the Kinetics and Cellular Characteristics of Corneal Allograft Rejection Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 3899 - 3905. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Silverman, D. O. Zamora, Y. Pan, P. V. Texeira, S.-H. Baek, S. R. Planck, and J. T. Rosenbaum Constitutive and Inflammatory Mediator-Regulated Fractalkine Expression in Human Ocular Tissues and Cultured Cells Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1608 - 1615. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |